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ab
stract
PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas
(DLBCLs) and has been associated with poor prognosis in many studies. The impact ofMYC-R on prognosis may
be influenced by theMYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of
patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of
MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene.
METHODS The study cohort included patients with histologically confirmed DLBCL morphology derived from
large prospective trials and patient registries in Europe and North America who were uniformly treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy or the like. Fluorescence
in situ hybridization for the MYC, BCL2, BCL6, and IG heavy and light chain loci was used, and results were
correlated with clinical outcomes.
RESULTS A total of 5,117 patients were identified of whom 2,383 (47%) had biopsy material available to assess
for MYC-R. MYC-R was present in 264 (11%) of 2,383 patients and was associated with a significantly shorter
progression-free and overall survival, with a strong time-dependent effect within the first 24 months after di-
agnosis. The adverse prognostic impact ofMYC-R was only evident in patients with a concurrent rearrangement
of BCL2 and/or BCL6 and an IG partner (hazard ratio, 2.4; 95% CI, 1.6 to 3.6; P , .001).
CONCLUSION The negative prognostic impact ofMYC-R in DLBCL is largely observed in patients withMYC double
hit/triple-hit disease in whichMYC is translocated to an IG partner, and this effect is restricted to the first 2 years
after diagnosis. Our results suggest that diagnostic strategies should be adopted to identify this high-risk cohort,
and risk-adjusted therapeutic approaches should be refined further.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
MYC rearrangement (MYC-R) occurs in approximately
10% to 15% of diffuse large B-cell lymphomas
(DLBCLs), and several studies have suggested an
inferior progression-free survival (PFS) and overall
survival (OS) compared with patients without MYC-
R.1-9 For large B-cell lymphomas that carry MYC and
BCL2 and/or BCL6 translocations (double-hit [DH]/
triple-hit [TH] lymphoma), the current WHO classifi-
cation now includes a new entity termed high-grade
B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangement, which has been associated with a poor
prognosis after standard treatment with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP).10,11 As a consequence, fluo-
rescence in situ hybridization (FISH) testing for
MYC-R, followed by BCL2 and BCL6 loci if MYC-R is
present, has become routine practice in many in-
stitutions, and the presence of MYC-DH/TH often
triggers a distinct, sometimes more intensive thera-
peutic approach.
However, many questions about the role of MYC-R
remain. The negative prognostic implication of a single-
hit (SH) MYC-R has been reported variably. In
addition, the partner gene associated with MYC-R,
which can be either an immunoglobulin (IG) heavy
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chain or light chain or a non-IG locus,12 may affect out-
come.3 Given the relatively small sample sizes in previous
studies, the prognostic impact ofMYC-SH andMYC-DH/TH
within the context of theMYC translocation partner (MYC-IG
v MYC-non-IG) in DLBCL has been reported inconsis-
tently. Similarly, the prognostic implication of DH lym-
phoma with MYC-R and BCL6 rearrangement is also
controversial.3,10,13-15 The Lunenburg Lymphoma Bio-
marker Consortium (LLBC) set out to address these
questions in a large cohort of patients with DLBCL who were
uniformly treated with R-CHOP or R-CHOP–like immu-
nochemotherapy within prospective clinical trials and
population-based settings.
METHODS
DLBCL Cohorts
The LLBC compiled a cohort of patients with de novo,
CD20+ DLBCL treated with curative intent with R-CHOP or
R-CHOP–like immunochemotherapy, including patients
enrolled in prospective clinical trials (The Lymphoma Study
Association [LYSA]: LNH01-5B and LNH03-B16-19; German
Study Group for High-Grade Non-Hodgkin’s Lymphoma:
RICOVER20 and MegaCHOEP21; Hemato-Oncology Foun-
dation for Adults in the Netherlands [HOVON]: HOVON 46
and HOVON 84) and from population-based registries with
available clinical data (Leeds/Haematological Malignancy
Research Network [United Kingdom], Barts Cancer In-
stitute [United Kingdom], Stanford Cancer Institute [United
States], and BC Cancer [Canada]). Diagnostic samples
were reviewed by expert hematopathologists within each of
the contributing LLBC groups and classified according to
the current WHO classification.11 Of note, aggressive B-cell
lymphomas with morphologic features other than that of
DLBCL (ie, intermediate morphology between Burkitt
lymphoma and DLBCL or blastoid appearance) were not
included in the current study. The study was approved by
the ethics committees of all participating groups.
Immunohistochemistry and FISH Analysis
Immunohistochemical stains for MYC (clone EP121, also
known as Y69; Epitomics, Burlingame, CA) and BCL2
(clone 124; Dako, Glostrup, Denmark) were performed on
paraffin sections of tumors assembled in a tissue micro-
array (TMA) format (0.6-mm core diameter in duplicate)
according to standard protocols and scored in 10% in-
crements. DLBCL with 40% or greater MYC expression and
50% or greater BCL2 expression were designated dual-
expressor DLBCL. Additional subgroups included DLBCL
with MYC less than 40%/BCL2 less than 50%, MYC less
than 40%/BCL2 greater than 50%, and MYC greater than
40%/BCL2 less than 50% expression. FISH assays (either
on whole sections at the time of diagnosis or on the
same TMAs) to detect breakpoints in the MYC, BCL2, and
BCL6 loci (break-apart probes from Abbott Molecular, Des
Plaines, IL) underwent interlaboratory testing among all
participating groups before the study and demonstrated
very high rates of concordance (data not shown). DLBCL
cases that had a breakpoint in the MYC locus were tested
further for breaks in the BCL2 and BCL6 loci. In addition,
MYC-R cases were tested for MYC/IG heavy chain fusion
(Zytomed, Berlin, Germany) and, if negative, for MYC-IG
kappa and MYC-IG light chain double-color fusion.22 This
strategy allowed for the assignment of patients with DLBCL
to the following groups: DLBCL without MYC-R, MYC-SH
(IG),MYC-SH (non-IG),MYC-DH/TH (IG), andMYC-DH/TH
(non-IG). Cell of origin (COO) was assigned using the Hans
algorithm23 and/or gene expression–based assays.24
Statistical Analysis
The primary objective of the study was to validate the
prognostic relevance of MYC-SH and MYC-DH/TH status
within the context of theMYC translocation partner (MYC-IG
v MYC-non-IG) in patients with DLBCLmorphology. PFS was
defined as the time between diagnosis and the first event,
including death as a result of any cause or progression of
disease (with or without treatment response). OS was de-
fined as the time between diagnosis and death as a result of
any cause. For PFS and OS, patients were censored at the
latest date known to be alive. Variables were summarized by
numbers and percentages (excluding missing values) for
categorical data and by the mean and standard deviation
and median and quartiles for quantitative data. The prog-
nostic impact of MYC variables defined as rearranged (yes/
no), including breakpoint in the BCL2 and/or BCL6 loci (yes/
no), and IG partnership (IG v non-IG) on 5-year PFS and
5-year OS were estimated using the Kaplan-Meier method.
PFS and OS curves were compared using the log-rank test.
Median follow-up time was estimated using a reverse
Kaplan-Meier estimator.25,26 Cox proportional hazards re-
gression was used to assess the association of the MYC
variables and outcome. The models were stratified for the
source of data (clinical trials or registries). Univariable and
multivariable models were used to estimate hazard ratios
(HRs) and their 95% CIs. Multivariable models included the
International Prognostic Index (IPI) as the main confounder.
The IPI was considered in two categories (low, 0 to 2; high, 3
to 5). The proportional hazard assumption was tested with
Schoenfeld residuals.27 Whenever relevant, the proportional
hazard assumption was alleviated by dividing the time scale
in agreement with the residuals’ smoothing curves. A time-
dependent effect was introduced for the corresponding
variables that estimated effects before and after a given
threshold. All P values less than 5% were considered sta-
tistically significant. All analyses were performed using R
statistical software.28 The hazard rate was estimated using
cubic splines implemented in the survPen package.29,30
RESULTS
Patient Cohort
In total, 5,117 patients who met the criteria outlined in the
Methods were identified. Of these, 2,383 patients (1,003
2 © 2019 by American Society of Clinical Oncology
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from clinical trials and 1,380 from registries) had available
tissue samples suitable for TMA cores with evaluable FISH
results forMYC-R and complete clinical data and represent
the study cohort (Fig 1; Table 1). The study cohort was
largely representative of the overall cohort, with no major
discernible biases except for minor, nonsignificant differ-
ences in median age, IPI low versus high, Eastern Co-
operative Oncology Group performance status, number of
extranodal sites, and median follow-up. Within the study
cohort, median age was 65.7 years (interquartile range,
55.7-73.6 years), and median follow-up time was
74.7 months (95% CI, 73 to 76.7 months). Survival curves
of patients from each contributing group are shown in the
Data Supplement.
FISH Results
Of the 2,383 study patients with DLBCL, 264 (11%) had an
MYC-R, a proportion comparable with previously published
data.1,31 In 53 of the 264 patients, BCL2 and/or BCL6
rearrangement status could not be determined, and in 69 of
264 patients, the MYC partner gene (IG or non-IG) could
not be assessed because of limited material or failure in one
of the IG heavy or light chain FISH assays. Figure 1 shows
the distribution of patients according to FISH results. Within
the cohort of patients with full data on MYC-R and BCL2
and BCL6 rearrangements (n = 211), 72 (34%) had MYC-
SH, 82 (39%) had MYC-DH with BCL2, 31 (15%) had
MYC-DH with BCL6, and 26 (12%) had MYC-TH. Within
the cohort of patients with available data on MYC partner
gene status (n = 196), 107 (55%) had MYC-IG and 88
(45%) had MYC-non-IG. Details for patients within each
contributing group are listed in Data Supplement.
Clinical Characteristics and Outcome of MYC-R DLBCL
Patient characteristics are listed in Table 1. Compared with
patients with DLBCL without MYC-R, patients with DLBCL
withMYC-R were slightly older (P = .027), were more likely
to have stage III/IV disease (P = .009), had a poorer Eastern
Cooperative Oncology Group performance status (P = .006)
and were more likely to have numerous extranodal sites
Patients (N = 5,117)
Patients with missing samples
(n = 2,678)
Patients (n = 2,439)
Patients with
full clinical data
 (n = 2,383)
MYC-IG not
performed or failed
 (n = 69)
BCL2/BCL6 
not performed or failed
 (n = 53)
MYC-IG                                (n = 107)
MYC-non-IG                          (n = 88)
MYC-SH                                (n = 72)
MYC-DH BCL2                      (n = 82)
MYC-DH BCL6                      (n = 31)
MYC-TH                                (n = 26)
Patients with MYC-R
(n = 264)
Patients without MYC-R
(n = 2,119)
With missing IPI score    (n = 56)
   Ann Arbor stage           (n = 20)
   ECOG PS                         (n = 7)
   Extra nodal sites             (n = 5)
   LDH                                (n = 42)
FIG 1. Flowchart of the diffuse large B-cell
lymphoma study cohort. DH, double hit;
ECOG PS, Eastern Cooperative Oncology
Group performance status; IG, immuno-
globulin; IPI, International Prognostic In-
dex; LDH, lactate dehydrogenase;MYC-R,
MYC rearrangement; SH, single hit; TH,
triple hit.
Journal of Clinical Oncology 3
MYC Rearrangement in Diffuse Large B-Cell Lymphoma
Downloaded from ascopubs.org by University of York on September 16, 2019 from 144.032.065.162
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
(P = .002) and an elevated lactate dehydrogenase level
(P , .001; Table 1). Overall, the presence of MYC-R was
a predictor of inferior PFS and OS (Figs 2A and 2B). Of note,
a time-dependent effect on outcome forMYC-R was noted,
with the strongest impact within the first 2 years after di-
agnosis (PFS: HR, 1.7 [95% CI, 1.4 to 2.1]; OS: HR, 2.1
[95% CI, 1.7 to 2.7]). Beyond 24 months, the negative
impact ofMYC-R was not observed for either PFS (HR, 0.7;
95% CI, 0.4 to 1.2) or OS (HR, 0.8; 95% CI, 0.5 to 1.4). The
negative prognostic impact of MYC-R was independent of
the variables within the IPI (PFS: HR, 1.6 [95% CI, 1.3 to
2.0]; OS: HR, 2.0 [95% CI, 1.6 to 2.5]).
We next analyzed the impact of MYC-SH versus MYC-DH/
TH on clinical outcome. As expected, DLBCL with MYC-
DH/TH had inferior PFS and OS compared with DLBCL
withoutMYC-R (Figs 2C and 2D). Again, there was a strong
effect on outcome only within the first 2 years after di-
agnosis (PFS: HR, 1.8 [95% CI, 1.3 to 2.4]; OS: HR, 2.4
[95% CI, 1.8 to 3.3]). Of note, within the group withMYC-R
DLBCL, the presence ofMYC-SH affected neither PFS (HR,
1.2; 95% CI, 0.8 to 1.7) nor OS (HR, 1.3; 95% CI, 0.9 to
2.0). On multivariable analysis, including the IPI score (low/
high), presence ofMYC-SH andMYC-DH/TH, and the time
interval before and after 24 months postdiagnosis, only the
IPI and presence of MYC-DH/TH (as a variable before 24
months) were significant predictors of PFS (both P, .001;
Table 2), whereas the presence of MYC-SH was not sig-
nificant (P = .25). Multivariable analysis that evaluated
predictors of OS demonstrated similar findings.
DLBCL With MYC-DH Involving BCL6
In patients with DLBCL morphology, MYC-DH that involves
BCL6 is less commonly encountered thanMYC-DH/THwith
BCL2, and studies have yielded controversial results about
its clinical relevance in view of small cohort sizes.3,10,12-15
Our study cohort included 31 patients with MYC-DH with
BCL6 rearrangement, and we found no evidence of a dif-
ference in outcome (PFS, OS) compared with patients with
MYC-DH with BCL2 rearrangement or those with the
presence of an MYC-TH constellation (Fig 3).
Prognostic Implications of the MYC-R Partner (IG
v Non-IG)
We analyzed the impact of the MYC-R partner gene (IG v
non-IG) on PFS and OS. Among patients with MYC-R, only
those with MYC-DH/TH in which MYC was rearranged with
an IG partner (MYC-IG) demonstrated inferior outcome
(Fig 4). The early effect was again evident in the analysis
(PFS: HR, 2.9 [95% CI, 2.0 to 4.3]; OS: HR, 3.6 [95% CI,
2.5 to 5.4]) within 24 months after diagnosis. Patients with
MYC-SH (either IG or non-IG) and those with MYC-DH/TH
non-IG had an outcome comparable with those with DLBCL
without MYC-R (MYC negative). In multivariable Cox pro-
portional hazards regression models for PFS and OS that
included the various MYC subgroups, the time-dependent
effect and the IPI demonstrated a significant impact of the
TABLE 1. Clinical and Biologic Characteristics of the DLBCL Study Cohort
Patients, No. (%)
Characteristic All Without MYC-R With MYC-R
No. of patients 2,383 2,119 (88.9) 264 (11.1)
Data source
Registries 1,380 (57.9) 1,215 (57.3) 165 (62.5)
Trials 1,003 (42.1) 904 (42.7) 99 (37.5)
IPI score
0-2 1,374 (57.7) 1,250 (59.0) 124 (47.0)
3-5 1,009 (42.3) 869 (41.0) 140 (53.0)
Missing 0 0 0
Age, years
# 60 798 (33.5) 726 (34.3) 72 (27.3)
. 60 1,584 (66.5) 1,392 (65.7) 192 (72.7)
Missing 1 1 0
Ann Arbor stage
I/II 938 (39.7) 854 (40.6) 84 (32.1)
III/IV 1,425 (60.3) 1,247 (59.3) 178 (67.9)
Missing 20 18 2
ECOG performance status
# 1 1,933 (81.3) 1,736 (82.2) 197 (74.9)
1 443 (18.6) 377 (17.8) 66 (25.1)
Missing 7 6 1
No. of extra nodal sites
# 1 1,797 (75.6) 1,618 (76.5) 179 (67.8)
1 581 (24.4) 496 (23.5) 85 (32.2)
Missing 5 5 0
Lactate dehydrogenase
Normal 1,042 (45.5) 957 (46.9) 85 (34.1)
Elevated 1,248 (54.5) 1,084 (53.1) 164 (65.9)
Missing 93 78 15
MYC
Negative 2,119 (92.8) 2,119 (100)
SH (IG) 40 (1.7) 40 (27.2)
DH/TH (IG) 54 (2.4) 54 (36.7)
SH (non-IG) 17 (0.7) 17 (11.6)
DH/TH (non IG) 53 (2.3) 53 (36.0)
Missing 100 100
Death
Yes 1,536 (65.1) 819 (60.3) 717 (71.8)
No 822 (34.9) 540 (39.7 282 (28.2)
Progression
No 1,347 (58.6) 716 (53.5) 631 (65.7)
Yes 950 (41.4) 623 (46.5) 330 (34.3)
Abbreviations: DH, double hit; DLBCL, diffuse large B-cell lymphoma; ECOG,
Eastern Cooperative Oncology Group; IG, immunoglobulin; IPI, International
Prognostic Index; MYC-R, MYC rearrangement; SH, single hit; TH, triple hit.
4 © 2019 by American Society of Clinical Oncology
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MYC-DH/TH (IG) constellation (P , .001) and the IPI (P ,
.001), whereas all other variables were not significant
(Table 2).
Impact of MYC and BCL2 Expression and COO
on Outcome
A total of 1,414 patients with DLBCL with available im-
munohistochemical expression status of the MYC and
BCL2 proteins were available for analysis. Survival curves
(PFS, OS) for the four subgroups (with and without in-
cluding patients with MYC-DH/TH) are shown in the Data
Supplement. In accordance with numerous published
studies, dual-expressor DLBCL (40% or greater MYC ex-
pression and 50% or greater BCL2 expression) had an
inferior outcome (overall log-rank P , .001). The COO
assignment using the Hans algorithm (with and without
including patients with MYC-DH/TH) was prognostic in the
entire cohort (n = 1,919) and within the groups of clini-
cal trial and registry patients separately (n = 698 and
1,221, respectively). In line with previous results, MYC-R
was more frequent in germinal center B-cell–like (GCB)
DLBCL (16.6%) compared with non-GCB DLBCL (6.3%;
P , .001), and patients with MYC-DH that involved BCL2
and those withMYC-TH almost exclusively fell into the GCB
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FIG 2. Kaplan-Meier estimates of (A) progression-free survival (PFS) according to MYC-rearrangement (MYC-R); (B) overall survival (OS) according toMYC-
R; (C) PFS according to MYC single-hit (SH), double-hit (DH), or triple-hit (TH) constellation; and (D) OS according to MYC-SH, -DH, or -TH constellation.
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DLBCL subgroup, whereas those with MYC-DH that in-
volved BCL6 were found in both COO subgroups. MYC-SH
DLBCL that occurred in the non-GCB subgroup tended to
have an inferior outcome compared withMYC-SH DLBCL in
the GCB subgroup (P = .076 for OS).
DISCUSSION
Our study addresses a number of open questions about
MYC translocations in aggressive B-cell lymphomas with
DLBCL morphology. The 2017 WHO revision11 established
a new category of high-grade B-cell lymphomas with MYC
and BCL2 and/or BCL6 rearrangement. This decision was
influenced by emerging data from studies that demon-
strated inferior survival of patients with aggressive B-cell
lymphomas that carry anMYC translocation either alone or
in combination with a BCL2 and/or BCL6 translocation.2-9
As a consequence, the routine work-up of aggressive B-cell
non-Hodgkin lymphoma (B-NHL) at many institutions now
includes FISH testing for MYC-R and, if positive, for BCL2
and BCL6 loci. However, several unanswered issues re-
main. First, the diagnosis of high-grade B-cell lymphomas
with MYC and BCL2 and/or BCL6 rearrangement includes
various morphologies (Burkitt-like morphology, blastoid
appearance, and DLBCL morphology). Some studies
suggest that the negative prognostic impact of anMYC-DH/
TH constellation in aggressive B-NHL with DLBCL mor-
phology is less pronounced compared with lymphomas
with other morphologies.3,31 Second, the prognostic role of
the MYC translocation partner (IG v non-IG) has been
investigated in only a few and relatively small studies that
included aggressive B-NHL with different morphologies as
well as transformed lymphomas.5,12,32,33 A pivotal study by
Copie-Bergman et al3 that focused on aggressive B-NHL
with DLBCL morphology treated uniformly in prospective
clinical trials of the French Study Group of Adult Lym-
phoma/LYSA suggested that the negative prognostic im-
pact of MYC-R correlated with the MYC translocation
partner (IG v non-IG), although the number of DLBCLs that
showedMYC translocation with an IG or non-IG partner was
relatively small (n = 24 and 26, respectively). With the
inclusion of these DLBCLs from the French Study Group of
Adult Lymphoma/LYSA, our study now comprises 94
DLBCL tumors withMYC-R to an IG gene locus and 70 with
MYC-R to a non-IG locus, which is the largest series in our
knowledge reported to date.
In this study, the LLBC, whose members represent leading
trial groups or registries in Europe and North America,
addressed some of the existing controversies. Of note,
we focused on aggressive B-NHLs with DLBCL morphol-
ogy that were treated uniformly with an R-CHOP or
R-CHOP–like therapy. A uniform and thorough FISH
strategy (in particular for the light-chain loci) included an
interlaboratory validation procedure among the partici-
pating centers before the pooling of the clinical and
FISH data.
In our large cohort of 2,383 patients with DLBCL, we
confirm the strong negative prognostic impact of the
TABLE 2. Multivariable Cox Proportional Hazards Regression Models for MYC-SH and MYC-DH/TH DLBCL (Model 1) and for MYC Variables,
Including IG/Non-IG Partners (Model 2)
PFS OS
Model HR (95% CI) P HR (95% CI) P
Model 1
MYC-negative 1 1
MYC-DH/TH before 24 months 1.67 (1.25 to 2.23) < .001 2.20 (1.64 to 2.96) < .001
MYC-DH/TH after 24 months 0.42 (0.17 to 1.02) .055 0.44 (0.18 to 1.08) .073
MYC-SH 1.22 (0.82 to 1.80) .25 1.45 (0.96 to 2.18) .077
IPI low 1 1
IPI high 2.51 (2.18 to 2.90) < .001 2.83 (2.41 to 3.32) < .001
Model 2
MYC-negative 1 1
MYC-DH/TH (IG) before 24 months 2.43 (1.65 to 3.58) < .001 3.04 (2.05 to 4.60) < .001
MYC-DH/TH (IG) after 24 months 0.45 (0.11 to 1.81) .26 0.71 (0.23 to 2.21) .55
Other* 1.04 (0.74 to 1.48) .91 1.24 (0.87 to 1.77) .24
IPI low 1 1
IPI high 2.52 (2.18 to 2.91) < .001 2.82 (2.40 to 3.32) < .001
NOTE. Boldface indicates significance at P , .05.
Abbreviations: DH, double hit; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; IG, immunoglobulin; IPI, International Prognostic
Index; OS, overall survival; PFS, progression-free survival; SH, single hit; TH, triple hit.
*Other = MYC-SH (IG), MYC-SH (non-IG), and MYC-DH/TH (non-IG).
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presence of MYC-R on survival. By statistically analyzing
time-dependent effects, we demonstrated that this impact
was only evident within the first 2 years after the diagnosis.
Thus, the survival probability of patients withMYC-R DLBCL
who survived for at least 2 years did not differ from those
with DLBCL without MYC-R. This 2-year effect was also
evident in DLBCL with an MYC-SH and MYC-DH/TH
constellation when analyzed separately. However, although
MYC-DH/TH DLBCL clearly showed decreased PFS and
OS, the negative impact of MYC-SH was negligible and not
statistically significant. These data suggest that little justi-
fication exists for altering initial therapeutic approaches in
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patients with DLBCL whose tumors carry an MYC trans-
location alone (MYC-SH). However, for MYC-DH/TH DLBCL,
the major negative prognostic impact and 2-year effect
support the practice of optimizing first-line treatment ap-
proaches to achieve maximum complete response rates
because salvage treatment at relapse is not effective.34
Of note, our study provides additional evidence that the
survival rate for patients with MYC-DH/TH lymphoma with
DLBCL morphology may be significantly better (ap-
proximately 60% after 5 years) compared with those
with MYC-DH/TH lymphoma with Burkitt-like or blastoid
morphology.5,32,34,35 This finding supports the statement
in the updated WHO classification11 that the morphology
of the tumor cells should be provided in the pathology
report when the diagnosis of a high-grade B-cell lym-
phoma withMYC andBCL2 and/or BCL6 rearrangement is
made. Potential consequences of this morphologic in-
formation for treatment purposes, however, remain un-
clear. Furthermore, the outcomes are superior to those
previously reported for tumors with DLBCL morphology
treated with R-CHOP.10 This likely reflects a historic se-
lection bias in FISH testing of patients with high-risk
features that was mitigated in the current study by ap-
plying FISH to all tumors.
Our data also contribute to the open question of whether
DLBCL withMYC-R and BCL6 rearrangement differ clinically
fromMYC/BCL2 orMYC/BCL2/BCL6 rearrangement.3,10,12-15
Differences could be expected becauseMYC/BCL6-positive
DLBCL at least partially falls into the group of activated
B-cell DLBCL, whereas DLBCL with MYC/BCL2 or MYC/
BCL2/BCL6 rearrangement almost exclusively belongs
in the group of GCB DLBCL.1 Our series of 31 patients
with DLBCL with an MYC/BCL6 double represents, in our
knowledge, the largest number of such patients reported to
date and shows no differences in clinical features, in-
cluding IPI factors or survival outcomes compared with
other MYC-DH/TH DLBCLs.
Our study also confirms a prior report that the type of the
MYC translocation partner (IG v non-IG) has a prognostic
impact. Non-IG translocation partners ofMYC in aggressive
B-cell lymphomas include PAX5, BCL6, and IKAROS,
among many others.36 Whether the juxtaposition of MYC to
enhancers of these genes has different biologic conse-
quences compared with the juxtaposition of MYC to IG
enhancers is not well studied.3,12 Also unclear is whether
the MYC translocation partner affects the recently estab-
lished DH gene expression or molecular high-grade
signatures.37,38 Our data strongly suggest that patients with
DLBCL in which MYC is rearranged to a non-IG partner do
not differ in outcomes from those with DLBCL withoutMYC-
R. Of note, this also holds true for patients withMYC-DH/TH
DLBCL in which the MYC partner is a non-IG gene. The
finding that only patients with DLBCL-DH/TH in whichMYC
is rearranged to an IG partner have significantly worse PFS
and OS might have two major implications. First, future
FISH strategies in DLBCL may have to include the IG light-
chain loci in cases where MYC is rearranged, and second,
risk-adjusted therapeutic approaches in DLBCL may be
needed only for MYC-DH/TH cases in which MYC is
rearranged to an IG partner. Because the large impact of
this genetic constellation seems to be restricted to the first
2 years after diagnosis, emphasis should be given to op-
timizing first-line treatment and consolidation after com-
plete remission. Thus, the MYC effect is a compelling
biologic contributor to the 2-year event-free survival/PFS
effect seen in many prospective studies of DLBCL that was
proposed and further validated as a surrogate end point in
several large studies.39,40
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